Mallinckrodt’s Hepatorenal Syndrome Drug Terlipressin Gets A Virtual AdComm

US FDA cardiovascular and renal drugs panel will weigh approvability of the vasopressin analog during a nine-hour, online meeting 15 July; terlipressin was the focus of a 2009 complete response letter but met its primary endpoint in the recent CONFIRM trial.

Hepatorenal syndrome : are you at risk ? Yes or no
Terlipressin could become the first drug approved in the US for hepatorenal syndrome type 1. • Source: Shutterstock

Mallinckrodt plc will become the second sponsor to virtually present and defend a drug application before a US Food and Drug Administration advisory committee with the 15 July review of terlipressin, a vasopressin analog.

The Cardiovascular and Renal Drugs Advisory Committee will meet via an online teleconferencing platform to consider terlipressin lyophilized powder for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers